ARTICLE | Clinical News

NY-ESO-1 immunotherapy: Therion began a dose-ranging European Phase I trial of its NY-ESO-1 immunotherapy, which uses rV-NY-ESO-1 and rF-NY-ESO-2 in a prime-boo

January 7, 2002 8:00 AM UTC

Therion Biologics Corp., Cambridge, Mass. Product: NY-ESO-1 immunotherapy Business: Cancer Therapeutic category: Immune stimulation Target: NY-ESO-1-expressing tumor cells Description: Recombinant vac...